A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Latest Information Update: 09 Sep 2022
At a glance
- Drugs Lirentelimab (Primary)
- Indications Allergic conjunctivitis; Keratoconjunctivitis
- Focus Adverse reactions; Proof of concept
- Acronyms KRONOS
- Sponsors Allakos
- 04 Apr 2022 Results published in the Journal of Allergy and Clinical Immunology.
- 21 May 2020 According to an Allakos media release, data from the study will be presented at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2020.
- 16 Mar 2020 Results published on 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology